Fountain Therapeutics: an AI-based platform to reverse cellular aging
Fountain’s AI-driven platform measures cellular age as the basis for anti-aging drug screens
Fountain is using an unbiased data-driven approach to identify compounds that reverse the biological process of aging, and in contrast to the traditional disease hypothesis-driven approach, the company is agnostic to indication.
“Eighty percent of the healthcare world is in our purview as an aging-related disease company,” CEO John Dimos told BioCentury. “The way we are looking to discover and develop drugs might be changing as we start focusing more on aging as the root cause of many of these diseases.” ...